** Drug developer Eton Pharmaceuticals' ETON.O shares rise 6.2% to $15.51 premarket
** Company says its experimental drug, ET-600, passed a bioequivalence study against an FDA-approved reference product with the same active ingredient for treatment of a rare condition called central diabetes insipidus $(CDI.NZ)$
** A bioequivalence study compares a generic test formulation with the original reference drug
** CDI is an uncommon problem in which the body can't properly balance fluid levels prompting to make large amounts of urine
** Eton Pharma plans to file FDA marketing application in April 2025
** As of last close, company's shares have more than tripled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。